A number of firms have modified their ratings and price targets on shares of Versigent (NYSE: VGNT) recently:
- 10/15/2026 – Versigent was downgraded by Zacks Research from “hold” to “strong sell”.
- 10/12/2026 – Versigent had its price target raised by Royal Bank Of Canada from $52.00 to $53.00. They now have an “outperform” rating on the stock.
- 10/8/2026 – Versigent was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
- 10/6/2026 – Versigent had its price target lowered by The Goldman Sachs Group, Inc. from $59.00 to $58.00. They now have a “buy” rating on the stock.
Versigent Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, September 18th. Shareholders of record on Friday, September 4th were given a dividend of $0.13 per share. The ex-dividend date of this dividend was Friday, September 4th. This represents a $0.52 annualized dividend and a yield of 1.2%.
Insiders Place Their Bets
In other Versigent news, Director Kevin Clark sold 47,761 shares of the firm’s stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $44.36, for a total value of $2,118,677.96. Following the sale, the director owned 27,571 shares of the company’s stock, valued at $1,223,049.56. This trade represents a 63.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 220,000 shares of company stock worth $10,065,848.
Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.
Read More
- Five stocks we like better than Versigent
- Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over
- Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling?
- Halliburton Gains Traction: Multiyear Upcycle Ahead
- Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
